High CBF and cNSE could be useful markers for prediction of SAE. SAE impairs neurodevelopmental scales at 6 months.

Few preliminary reports studied the utility of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) for differentiation between infantile hemangiomas (IHs) and vascular malformations. The aim of this study was to investigate the role of serum VEGF and bFGF levels in differentiating IHs from vascular malformations and identifying the stage and clinical course of IHs. Serum levels of VEGF and bFGF were assessed in 60 infants and children with various cutaneous vascular anomalies defined in 3 groups: proliferating IHs (n = 25), involuting IHs (n = 23), and vascular malformations (n = 12), in comparison with their levels in 40 healthy matched control. Serum levels of VEGF and bFGF were significantly elevated in all groups as compared to control ( P < .001, respectively). Both proliferating and involuting IHs had comparable levels of both markers ( P > .05, respectively) that were significantly higher in comparison with vascular malformations ( P < .05, respectively). Significantly lower VEGF levels were found in IHs that had regressed spontaneously (n = 11) compared to those regressed by treatment (n = 37), ( P < .05); meanwhile, bFGF showed no significant difference between both groups ( P > .05). Using receiver operating characteristic curves, a combined use of VGEF and bFGF yielded a sensitivity of 85.42% and a specificity of 100% for differentiating IHs from vascular malformations. Serum VEGF and/or bFGF levels are increased in cutaneous vascular anomalies and can differentiate IHs from vascular malformations. None of these markers could help in identifying the stage of IHs. Low VEGF is associated with spontaneous regression of IHs.

Background: iron is essential element involved in a broad range of biologically important reactions critical for cellular function and also plays a role in oxygen transferring and despite its low daily requirements iron deficiency is the most common nutritional disorder in the world. Increased serum concentration of TfR is a sensitive and quick response to the development of iron deficiency. Conversely, the serum TfR concentration decreases in response to treatment with iron before a change in hemoglobin occurs, so the response to iron can be monitored by changes in serum TfR. TfR-F index is proposed to be a more accurate reflection of tissue iron status than ferritin. Many factors can influence the iron status of the fetus at birth, Maternal diabetes mellitus was thought to be associated with depletion of fetal iron stores in proportion to the degree of maternal control and presence or absence of complications of diabetes, but not maternal iron status. Aim of the work: in this study we aimed to assess the effect of maternal diabetes on neonatal cord blood iron stores. Patient and Method: this case-control study was conducted on 100 maternal/cord blood pairs who were randomly included in the study from Obstetrics and Gynecology Department at El-Nile Insurance Hospital, Shubra El Khema, during the period from November 2015 to July 2016. Results: this study was done on the fetal iron status in the diabetic mothers and the control group using the transferrin receptos-ferritin index(TfR-F index) as a measure of cellular iron status and results showed that infants of the diabetic mothers(IDM) had significantly lower iron stores represented as lower s.ferritin (P=0.000) and significantly higher serum transferring receptors(STfR)levels than infants born to the control mothers (P=0.038) and also higher sTfR level in insulin dependent diabetes mellitus (IDDM) mothers ; this was suggesting a state of increased erythropoiesis. Conclusion: this study confirmed that iron stores are lower at birth in infants of women with diabetes mellitus. This appeared to be due to the effects of increased erythropoiesis secondary to chronic intrauterine hypoxia. Fetal iron stores were affected by maternal glycemic control and not related to maternal iron supplement.

Background: Ischemia modified albumin (IMA) rises promptly after an ischemic event and stays elevated for several hours. However, a knowledge gap still exists in terms of the association between intrauterine growth restriction (IUGR) and IMA levels. Objective: The purpose of this study is to ascertain any potential relationships between cord blood IMA levels and IUGR in preterm newborns with or without complex gestations, Methods: A prospective case-control study included 80 mothers of preterm neonates (<37 gestational weeks). Based on antenatal ultrasound findings, eligible women were divided into two groups: case group including the women diagnosed antenatally with IUGR, and control group including women with normal fetal development. The analysis and quantification of the IMA levels was done using a double-antibody sandwich ELISA kit Results: The albumin level was significantly lower in the case group compared to the control group (3.18 ± 0.28 versus 3.88 ± 0.49; p <0.001), while the IMA level was significantly higher in the case group compared to the other group (145 (97.5 -210) versus 40 (25-90); p <0.001). At a cut-off point of ≤ 3.4, the albumin had an AUC of 0.993, a sensitivity of 95%, and a specificity of 87.5% for differentiating IUGR. While the cut-off point of IMA of >50 had an AUC of 0.850, a sensitivity of 92.5%, and a specificity of 67.5% for prediction of IUGR. Conclusion:The levels of IMA and albumin in the cord blood have a strong correlation with the IUGR.